William Yoon1, Amer Alame2, Richard Berri2. 1. Department of Surgery, Section of Surgical Oncology, St John Hospital and Medical Center, Van Elslander Cancer Center, Detroit, MI 48236, USA. Electronic address: william.yoon@stjohn.org. 2. Department of Surgery, Section of Surgical Oncology, St John Hospital and Medical Center, Van Elslander Cancer Center, Detroit, MI 48236, USA.
Abstract
BACKGROUND: We evaluated the clinical utility of the Peritoneal Surface Disease Severity Score (PSDSS) as a preoperative predictor of resectability in the treatment of peritoneal surface malignancies. METHODS: Forty-nine patients were selected for cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and were stratified according to the PSDSS retrospectively. RESULTS: Of 52 cytoreductive surgeries performed in 49 patients, HIPEC was performed in 33 cases (63%). We analyzed 31 cases of appendiceal and colorectal cancer patients who underwent CRS and HIPEC and 12 who underwent CRS only. 68% of the patients in whom CRS and HIPEC was performed were classified as PSDSS stage I or II. Contrastingly, all patients in whom CRS and HIPEC was unachievable were scored as PSDSS stage III or IV. CONCLUSIONS: The outcomes of this study suggest that the PSDSS can be used as a preoperative assessment tool to predict disease resectability in the treatment of peritoneal surface malignancies.
BACKGROUND: We evaluated the clinical utility of the Peritoneal Surface Disease Severity Score (PSDSS) as a preoperative predictor of resectability in the treatment of peritoneal surface malignancies. METHODS: Forty-nine patients were selected for cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and were stratified according to the PSDSS retrospectively. RESULTS: Of 52 cytoreductive surgeries performed in 49 patients, HIPEC was performed in 33 cases (63%). We analyzed 31 cases of appendiceal and colorectal cancerpatients who underwent CRS and HIPEC and 12 who underwent CRS only. 68% of the patients in whom CRS and HIPEC was performed were classified as PSDSS stage I or II. Contrastingly, all patients in whom CRS and HIPEC was unachievable were scored as PSDSS stage III or IV. CONCLUSIONS: The outcomes of this study suggest that the PSDSS can be used as a preoperative assessment tool to predict disease resectability in the treatment of peritoneal surface malignancies.
Authors: Fernando Mendoza-Moreno; Manuel Diez-Alonso; Belén Matías-García; Enrique Ovejero-Merino; Remedios Gómez-Sanz; Alma Blázquez-Martín; Ana Quiroga-Valcárcel; Cristina Vera-Mansilla; Raquel Molina; Alberto San-Juan; Silvestra Barrena-Blázquez; Miguel A Ortega; Melchor Alvarez-Mon; Alberto Gutiérrez-Calvo Journal: J Clin Med Date: 2022-08-22 Impact factor: 4.964